Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Open-label, Multi-center, Flexible Dose Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

NCT01371708 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01371708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01371708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Open-label, Multi-center, Flexible Dose Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 2, 2012
Completion date
April 22, 2016
Enrollment
283 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder